Trillium Therapeutics Inc.·4

Mar 15, 5:12 PM ET

Uger Robert 4

4 · Trillium Therapeutics Inc. · Filed Mar 15, 2021

Insider Transaction Report

Form 4
Period: 2021-03-12
Uger Robert
Chief Scientific Officer
Transactions
  • Exercise/Conversion

    Common Shares

    2021-03-12$3.39/sh+2,917$9,8962,917 total
  • Sale

    Common Shares

    2021-03-12$11.97/sh2,917$34,9160 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2021-03-122,91758,333 total
    Exercise: $3.39Exp: 2028-11-08Common Shares (2,917 underlying)
Footnotes (3)
  • [F1]This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
  • [F2]The exercise price of these options is $4.23 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.8020 USD.
  • [F3]25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months.

Documents

1 file
  • 4
    form4.xmlPrimary

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES